Chadi Nabhan, Chief Medical Officer and Head of Strategy at Ryght, shared a post on X:
“My full healthcare unfiltered EXPRESS podcast with Dr. Deva Mahalingam, first author on the Nature Medicine paper showing Elraglusib activity in Pancreatic Cancer is here.
What is next and what was the rationale for the study?
Here is the paper, recently published.”
Title: Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Authors: Devalingam Mahalingam, Rachna T. Shroff, Benedito A. Carneiro, Yan Ji, Andrew L. Coveler, Andres Cervantes, Vaibhav Sahai, Anne Ploquin, Sandrine Hiret, Noelle K. LoConte, Ivor J. Percent, Charles D. Lopez, Simon Pernot, Petr Kavan, Mary Mulcahy, Ryan Carr, Francis J. Giles, Chris Seifarth, Andrey Ugolkov, Taylor Weiskittel, Gil Fine, Mark Jaros, Andrew P. Mazar and Tanios S. Bekaii-Saab
Other articles featuring Chadi Nabhan on OncoDaily.